ReGen today reported a successful outcome to its exploratory Phase IIa clinical trial of zolpidem for the treatment of the dormancy associated with neurological injury. The trial achieved its objective of showing it is possible to obtain a non-sedating dose. Furthermore, the novel sublingual spray formulation tested may offer some additional advantages in terms of speed of onset over the conventional oral tablet. The next step will to confirm the neurological effect with this dose regime.

Unlock the rest of this article with a 14 day trial

or Unlock with your email

Already have an account?
Login here